NCT04856176View on ClinicalTrials.gov

A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

December 6, 2024

Study Completion Date

December 6, 2024

Conditions
Advanced Lung Non-Small Cell CarcinomaNon-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions
DRUG

Granulocyte-Macrophage Colony-Stimulating Factor

250 mcg

DRUG

Pembrolizumab

200mg every 3 weeks

DRUG

pemetrexed

500mg/m2

DRUG

Paclitaxel

200mg/m2

DRUG

Carboplatin

AUC 5/6

Trial Locations (1)

02111

Tufts Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Partner Therapeutics, Inc.

INDUSTRY

lead

Tufts Medical Center

OTHER

NCT04856176 - A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | Biotech Hunter | Biotech Hunter